Biopharmaceutical firm Biocon has received marketing authorisation from the European Commission for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across multiple disease stages in the European Union.

The Bengaluru-headquartered company announced the approval in a regulatory filing on Wednesday, 18 November. The authorisation allows Biocon to market and sell the medicine across the European Union.

Biocon's pertuzumab is the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency's new tailored clinical approach, the company said. The pathway is designed to streamline how biosimilars are assessed, and Pebrilzo is the first product to complete it.

The approval follows a positive opinion from the Committee for Medicinal Products for Human Use, the European Medicines Agency's scientific committee, issued on 17 September 2026. It also comes after a recent approval from the United States Food and Drug Administration for the same biosimilar.

What Pebrilzo is used for

Pebrilzo has been approved as a 420 mg concentrate for solution for infusion. Pertuzumab is a monoclonal antibody that binds to the human epidermal growth factor receptor 2, known as HER2, and inhibits the growth of tumour cells that overproduce the receptor.

The biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence.

It is also indicated in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence, and in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for their metastatic disease.

HER2-positive breast cancer is a form of the disease in which the cancer cells produce too much of the HER2 protein, which can make the cancer grow and spread more quickly. Treatments that target HER2 have become a central part of care for these patients.

Fifth oncology biosimilar in Europe and the US

Biocon chief executive and managing director Shreehas Tambe said the European Commission approval marks a significant regulatory milestone for the company.

"With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer," he said.

Biosimilars are medicines designed to be highly similar to an already approved biological medicine, known as the reference product. They are intended to offer the same treatment benefit, usually at a lower cost, which can widen access for patients and ease pressure on health systems.

Biocon is one of India's largest biopharmaceutical companies and has built a substantial biosimilars business spanning oncology, diabetes and other therapy areas. The European approval adds to a portfolio that already includes products cleared in both the European Union and the United States.

For patients, the practical significance of a new biosimilar approval is greater choice and, over time, potentially lower treatment costs as more versions of a medicine become available. The approval does not by itself set the price at which Pebrilzo will be sold in individual European countries, which will depend on national pricing and reimbursement decisions.